Reactive oxygen species: Stuck in the middle of neurodegeneration

Journal of Alzheimer's Disease

Volumn 20, Issue SUPPL.2, 2010, Pages

  Patten, David A ^a   Germain, Marc ^a   Kelly, Melissa A ^a   Slack, Ruth S ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Apoptosis; autophagy; mitochondria; neurodegeneration; reactive oxygen species

Indexed keywords

AMYLOID BETA PROTEIN; APOPTOSIS INDUCING FACTOR; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; BH3 PROTEIN; CASPASE 9; CELL NUCLEUS DNA; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME C; DJ 1 PROTEIN; ENDONUCLEASE G; GLUTATHIONE PEROXIDASE; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIA TARGETED UBIQUINOL; MUTANT PROTEIN; PARKIN; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOPHAGY; CELL DAMAGE; CELL DEATH; CLINICAL ASSESSMENT; CYTOSOL; DEGENERATIVE DISEASE; HUNTINGTON CHOREA; MITOCHONDRION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

EID: 77956216928     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100498     Document Type: Review

References (106)

1. Babior BM (2000) The NADPH oxidase of endothelial cells. IUBMB Life 50, 267-269.
2. Yokoyama Y, Beckman JS, Beckman TK, Wheat JK, Cash TG, Freeman BA, Parks DA (1990) Circulating xanthine oxidase: potential mediator of ischemic injury. Am J Physiol 258, G564-G570.
3. Dijkstra G, Moshage H, van Dullemen HM, de Jager-Krikken A, Tiebosch AT, Kleibeuker JH, Jansen PL, van Goor H (1998) Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol 186, 416-421.
4. Orrenius S (2007) Reactive oxygen species in mitochondria- mediated cell death. DrugMetab Rev 39, 443-455.
5. Andreyev AY, Kushnareva YE, Starkov AA (2005) Mito- chondrial metabolism of reactive oxygen species. Biochemistry (Mosc) 70, 200-214.
6. Muller FL, Liu Y, Van Remmen H (2004) Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 279, 49064-49073.
7. Zhang DX, Gutterman DD (2007) Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am J Physiol Heart Circ Physiol 292, H2023-2031.
8. Lebovitz RM, Zhang H, Vogel H, Cartwright J, Jr., Dionne L, Lu N, Huang S, Matzuk MM (1996) Neurodegeneration, myocardial injury, and perinatal death in mitochondrial su- peroxide dismutase-deficient mice. Proc Natl Acad Sci U S A 93, 9782-9787.
9. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39, 44-84.
10. Groeger G, Quiney C, Cotter TG (2009) Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal 11, 2655-2671.
11. Babior BM (2004) NADPH oxidase. Curr Opin Immunol 16, 42-47.
12. Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86, 494-501.
13. Lassegue B, Griendling KK (2010) NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb VascBiol 30,653-661.
14. Paravicini TM, Touyz RM (2008) NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 31 Suppl 2, S170-S180.
15. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA (2003) Identification ofthe NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 278, 12029-12038.
16. de Vries HE, Witte M, Hondius D, Rozemuller AJ, Drukarch, Hoozemans J, van Horssen J (2008) Nrf2-induced an- tioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radic Biol Med 45, 1375-1383.
17. Itoh K, Wakabayashi N, Katoh Y, Ishii T, O'Connor T, Ya- mamoto M (2003) Keap1 regulates both cytoplasmic-nuclear shuttling and degradation ofNrf2 in response to electrophiles. Genes Cells 8, 379-391.
18. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP (2006) DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 103, 15091-15096.
19. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732.
20. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiran- ti V, Zeviani M, Scarpulla RC, Chandel NS (2005) Oxygen sensing requires mitochondrial ROS but not oxidative phos- phorylation. Cell Metab 1, 409-414.
21. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, Schumacker PT (2005) Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. CellMetab 1, 401-408.
22. Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP, Budinger GR, Chandel NS (2007) The Qo site of the mi- tochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol 177, 1029-1036.
23. Bell EL, Klimova T, Chandel NS (2008) Targeting the mitochondria for cancer therapy: regulation ofhypoxia-inducible factor by mitochondria. AntioxidRedox Signal 10, 635-640.
24. Correia SC, Moreira PI (2010) Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration? J Neurochem 112, 1-12.
25. Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR, Andersen JK (2009) Inhibition of pro- lyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 284, 29065-29076.
26. Kamata H, Manabe T, Oka S, Kamata K, Hirata H (2002) Hydrogen peroxide activates IkappaB kinases through phos- phorylation of serine residues in the activation loops. FEBS Lett 519, 231-237.
27. Pahl HL (1999) Activators and target genes of Rel/NF- kappaB transcription factors. Oncogene 18, 6853-6866.
28. Das KC, Lewis-Molock Y, White CW (1995) Activation of NF-kappa B and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells. Am J Physiol 269, L588-602.
29. Gloire G, Piette J (2009) Redox regulation of nuclear post- translational modifications during NF-kappaB activation. An- tioxid Redox Signal 11, 2209-2222.
30. Bubici C, Papa S, Dean K, Franzoso G (2006) Mutual crosstalk between reactive oxygen species and nuclear factor- kappa B: molecular basis and biological significance. Onco- gene 25, 6731-6748.
31. Toledano MB, Leonard WJ (1991) Modulation of transcription factor NF-kappa B binding activity by oxidation- reduction in vitro. Proc Natl Acad Sci USA 88, 4328-4332.
32. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8, 275-283.
33. Tan M, Li S, Swaroop M, Guan K, Oberley LW, Sun Y (1999) Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem 274, 12061-12066.
34. Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, Ichimiya M, Sengupta S, Mechanic L, Okamura S, Hof- seth LJ, Moake M, Nagashima M, Forrester KS, Harris CC (2004) p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 64, 2350-2356.
35. Yoon KA, Nakamura Y, Arakawa H (2004) Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet 49, 134-140.
36. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006) TIGAR, a p53- inducible regulator of glycolysis and apoptosis. Cell 126, 107-120.
37. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM (2005) The antioxidant function of the p53 tumor suppressor. Nat Med 11, 1306-1313.
38. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2, 594-604.
39. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389, 300-305.
40. Liu B, Chen Y, St Clair DK (2008) ROS and p53: a versatile partnership. Free Radic Biol Med 44, 1529-1535.
41. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH, Jr., Beal MF (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69, 2064-2074.
42. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41, 646-653.
43. Schulz JB, Beal MF (1994) Mitochondrial dysfunction in movement disorders. Curr Opin Neurol 7, 333-339.
44. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8- hydroxyguanine levels in substantia nigra. J Neurochem 69, 1196-1203.
45. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA (2005) Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93, 953-962.
46. Mecocci P, MacGarvey U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36, 747-751.
47. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
48. Zimmerman MC, Oberley LW, Flanagan SW (2007) Mutant SOD1-induced neuronal toxicity is mediated by increased mitochondrial superoxide levels. J Neurochem 102, 609-618.
49. Boillee S, Vande Velde C, Cleveland DW (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39-59.
50. Vijayvergiya C, Beal MF, Buck J, Manfredi G (2005) Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J Neurosci 25, 2463-2470.
51. Ferri A, Cozzolino M, Crosio C, Nencini M, Casciati A, Gralla EB, Rotilio G, Valentine JS, Carri MT (2006) Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc Natl Acad Sci U S A 103, 13860-13865.
52. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39, 385-389.
53. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neu- rochem 79, 1246-1249.
54. Perez-Severiano F, Santamaria A, Pedraza-Chaverri J, Medina-Campos ON, Rios C, Segovia J (2004) Increased formation of reactive oxygen species, but no changes in glu- tathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation. Neurochem Res 29, 729733.
55. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22, 1592-1599.
56. Bueler H (2010) Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis, in press.
57. Liu W, Vives-Bauza C, Acin-Perez R, Yamamoto A, Tan Y, Li Y, Magrane J, Stavarache MA, Shaffer S, Chang S, Kaplitt MG, Huang XY, Beal MF, Manfredi G, Li C (2009) PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One 4, e4597.
58. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279, 18614-18622.
59. Krebiehl G, Ruckerbauer S, Burbulla LF, Kieper N, Maurer B, Waak J, Wolburg H, Gizatullina Z, Gellerich FN, Woitalla D, Riess O, Kahle PJ, Proikas-Cezanne T, Kruger R (2010) Reduced basal autophagy and impaired mitochondrial dynamics due to loss ofParkinson's disease-associated protein DJ-1. PLoS One 5, e9367.
60. Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C, Xia K, Jiang W, Ronai Z, Zhuang X, Zhang Z (2009) Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 119, 650-660.
61. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, V LD, Dawson TM, Ross CA (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria- dependent apoptosis. Hum Mol Genet 10, 919-926.
62. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anan- datheerthavarada HK (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. JBiol Chem 283, 9089-9100.
63. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK (2006) Parkinson's disease alpha- synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26, 41-50.
64. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449.
65. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD (2005) Mitochon- drial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEBJ19, 2040-2041.
66. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
67. Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80, 91-100.
68. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, Zhu X (2009) Impaired balance ofmitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29, 9090-9103.
69. Yu T, Robotham JL, Yoon Y (2006) Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA 103, 2653-2658.
70. Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, Casadesus G, Zhu X (2008) Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation ofmitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 105, 19318-19323.
71. Karuppagounder SS, Xu H, Shi Q, Chen LH, Pedrini S, Pech- man D, Baker H, Beal MF, Gandy SE, Gibson GE (2009) Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol Aging 30, 1587-1600.
72. Esteves AR, Arduino DM, Swerdlow RH, Oliveira CR, Cardoso SM (2009) Oxidative stress involvement in alpha- synuclein oligomerization in Parkinson's disease cybrids. An- tioxid Redox Signal 11, 439-448.
73. Batelli S, Albani D, Rametta R, Polito L, Prato F, Pesaresi M, Negro A, Forloni G (2008) DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS One 3, e1884.
74. Sheehan JP, Swerdlow RH, Miller SW, Davis RE, Parks JK, Parker WD, Tuttle JB (1997) Calcium homeostasis and reactive oxygen species production in cells transformed by mito- chondriafrom individuals with sporadic Alzheimer's disease. J Neurosci 17, 4612-4622.
75. LaFerla FM (2002) Calcium dyshomeostasis and intracellu- lar signalling in Alzheimer's disease. Nat Rev Neurosci 3, 862-872.
76. Isaacs AM, Senn DB, Yuan M, Shine JP, Yankner BA (2006) Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium. J Biol Chem 281, 2791627923.
77. Alberdi E, Sanchez-Gomez MV, Cavaliere F, Perez-Samartin A, Zugaza JL, Trullas R, Domercq M, Matute C (2010) Amyloid beta oligomers induce Ca(2+) dysregulation and neu- ronal death through activation ofionotropic glutamate receptors. Cell Calcium 47, 264-272.
78. He C, Klionsky DJ (2009) Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 43, 67-93.
79. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, Mizushima N (2006) Suppression of basal au- tophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885-889.
80. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K (2006) Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880-884.
81. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 12, 119-131.
82. Narendra D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183, 795-803.
83. Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, May J, Tocilescu MA, Liu W, Ko HS, Magrane J, Moore DJ, Dawson VL, Grailhe R, Dawson TM, Li C, Tieu K, Przedborski S (2010) PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U SA 107, 378-383.
84. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, Youle RJ (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 8, e1000298.
85. Festjens N, Vanden Berghe T, Vandenabeele P (2006) Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 1757, 1371-1387.
86. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR (2010) The BCL-2 Family Reunion. Mol Cell 37, 299-310.
87. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9, 47-59.
88. Cho BB, Toledo-Pereyra LH (2008) Caspase-independent programmed cell death following ischemic stroke. J Invest Surg 21, 141-147.
89. Mathai JP, Germain M, Marcellus RC, Shore GC (2002) Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53. Oncogene 21, 2534-2544.
90. Hubner A, Barrett T, Flavell RA, Davis RJ (2008) Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 30, 415-425.
91. Morel C, Carlson SM, White FM, Davis RJ (2009) Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol Cell Biol 29, 3845-3852.
92. Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, Hickman JA, Geneste O, Kroemer G (2007) Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBOJ 26, 2527-2539.
93. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushi- ma N, Packer M, Schneider MD, Levine B (2005) Bcl-2 an- tiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122, 927-939.
94. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B (2008) JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 30, 678-688.
95. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S, Auberger P (2010) Resveratrol promotes au- tophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 70, 1042-1052.
96. Scarlatti F, Granata R, Meijer AJ, Codogno P (2009) Does autophagy have a license to kill mammalian cells? Cell Death Differ 16, 12-20.
97. Smith RA, Adlam VJ, Blaikie FH, Manas AR, Porteous CM, James AM, Ross MF, Logan A, Cocheme HM, Trnka J, Prime TA, Abakumova I, Jones BA, Filipovska A, Murphy MP (2008) Mitochondria-targeted antioxidants in the treatment of disease. AnnNYAcadSci 1147, 105-111.
98. Jauslin ML, Meier T, Smith RA, Murphy MP (2003) Mitochondria-targeted antioxidants protect Friedreich Atax- ia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEBJ17, 1972-1974.
99. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cocheme HM, Murphy MP, Dominiczak AF (2009) Mitochondria-targeted antioxidant MitoQ10 improves en-dothelial function and attenuates cardiac hypertrophy. Hypertension 54, 322-328.
100. Antonenko YN, Roginsky VA, Pashkovskaya AA, Rokit- skaya TI, Kotova EA, Zaspa AA, Chernyak BV, Skulachev VP (2008) Protective effects of mitochondria-targeted an- tioxidant SkQ in aqueous and lipid membrane environments. JMembr Biol 222, 141-149.
101. Skulachev VP, Anisimov VN, Antonenko YN, Bakeeva LE, Chernyak BV, Erichev VP, Filenko OF, Kalinina NI, Kapelko VI, Kolosova NG, Kopnin BP, Korshunova GA, Lichinitser MR, Obukhova LA, Pasyukova EG, Pisarenko OI, Roginsky VA, Ruuge EK, Senin, II, Severina, II, Skulachev MV, Spivak IM, Tashlitsky VN, Tkachuk VA, Vyssokikh MY, Yaguzhin- sky LS, Zorov DB (2009) An attempt to prevent senescence: a mitochondrial approach. Biochim Biophys Acta 1787, 437461.
102. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH (2004) Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 279: 34682-34690
103. Zhao K, Luo G, Giannelli S, Szeto HH (2005) Mitochondria- targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol 70, 1796-1806.
104. Thomas DA, Stauffer C, Zhao K, Yang H, Sharma VK, Sze- to HH, Suthanthiran M (2007) Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. J Am Soc Nephrol 18, 213-222.
105. Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, Beal MF (2006) Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 98, 1141-1148.
106. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF (2009) Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Antioxid Redox Signal 11, 2095-2104.